The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons:
* Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we've seen in the recent price dips.
* Increased Debt Load: BSX is financing a significant portion of this deal (about $11 billion) with new debt. This has raised concerns about the company's leverage, with projections hitting 3.3x adjusted EBITDA leverage by the end of 2026.
* Valuation Premium: Some market participants feel the $14.5 billion price tag was high, leading to a "show me" period where the stock price remains under pressure until the integration proves successful.
### Expected Valuation Going Forward
Despite the near-term headwinds, the long-term outlook remains very bullish among analysts. Here is what is driving the expected valuation:
* Higher Growth Exposure: Penumbra operates in neurovascular and mechanical thrombectomy—markets growing at roughly 11% compared to BSX’s current 8% base. By 2028, BSX expects 60% of its revenue to come from these high-growth segments.
* Future Accretion: Analysts expect the deal to become neutral to slightly accretive in the second year, with significant earnings power thereafter as cost and revenue synergies kick in.
* Analyst Targets: The sentiment is overwhelmingly positive. We currently see:
* Buy Ratings: 33 analysts (including 7 "Strong Buys").
* Price Forecast: An average 1-year target of $129, with the highest estimates reaching $140. Given the current price around $92.51, this suggests substantial upside potential as the "volatility crush" from the acquisition news settles.
### Technical Snapshot for BSX
| Current Price | $92.51 |
| P/E Ratio | 49.47 |
| RSI (Relative Strength) | 39.08 (Approaching Oversold) |
| 40-Day LCL (Support) | $88.00 |
With an RSI near 39, the stock is nearing oversold territory, which might interest value-focused traders looking for an entry near the $88 support level.
Have other thoughts on Boston Scientific?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
1 commentsDisclaimer
The user Bill_S holds no position in NYSE:BSX. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
Pulsed Field Ablation And Minimally Invasive Therapies Will Reshape Long Term Procedure Volumes
View narrative
Future Growth Plans And Acquisitions Will Drive Broader Market Expansion
View narrative
Minimally Invasive Therapies And Atrial Fibrillation Treatments Will Support Steady Prospects Ahead
View narrative